Abdurasulova I N, Serdyuk S E, Gmiro V E
S. V. Anichkov Department of Neuropharmacology, I. P. Pavlov Department of Physiology, State Research Institute of Experimental Medicine, Russian Academy of Medical Sciences, St. Petersburg.
Bull Exp Biol Med. 2007 Aug;144(2):217-20. doi: 10.1007/s10517-007-0293-6.
We compared preventive and therapeutic effects of memantine, a selective blocker of NMDA-receptors, and IEM-1966, a blocker of both NMDA- and GluR1 AMPA-receptors, on the model of acute experimental allergic encephalomyelitis. Memantine in high doses prevented the development of experimental allergic encephalomyelitis only in 10% rats, slightly (by 1.4-1.5 times) moderated the neurological disturbances, and shortened the duration of the disease. In far lower doses, IEM-1966 prevented the development of experimental allergic encephalomyelitis in 50% rats, while in the affected rats it decreased the severity of neurological disturbances and duration of the disease by 3-4 times. When applied during the clinical phase of the disease, IEM-1966 decreased the severity of neurological disturbances and duration of the disease by 2.0-2.5 times predominantly in rats with mild and moderate course of experimental allergic encephalomyelitis.
我们比较了美金刚（一种N-甲基-D-天冬氨酸（NMDA）受体选择性阻滞剂）和IEM-1966（一种NMDA和α-氨基-3-羟基-5-甲基-4-异恶唑丙酸（AMPA）受体阻滞剂）对急性实验性过敏性脑脊髓炎模型的预防和治疗作用。高剂量美金刚仅在10%的大鼠中预防了实验性过敏性脑脊髓炎的发生，轻微（1.4至1.5倍）减轻了神经功能障碍，并缩短了疾病持续时间。IEM-1966以低得多的剂量在50%的大鼠中预防了实验性过敏性脑脊髓炎的发生，而在患病大鼠中，它将神经功能障碍的严重程度和疾病持续时间降低了3至4倍。在疾病临床阶段应用时，IEM-1966主要在实验性过敏性脑脊髓炎轻度和中度病程的大鼠中，将神经功能障碍的严重程度和疾病持续时间降低了2.0至2.5倍。
